UK markets closed
NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.92 -0.44 (-0.53%) GOLD FUTURES
2,333.20 -8.90 (-0.38%) DOW
38,500.04 -3.65 (-0.01%) Bitcoin GBP
51,597.98 -1,741.54 (-3.27%)
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 03:53PM EDT. Market open.
| Previous close | 67.03 |
| Open | 66.59 |
| Bid | 67.02 x 2600 |
| Ask | 67.11 x 200 |
| Day's range | 66.36 - 67.18 |
| 52-week range | 65.90 - 87.87 |
| Volume | |
| Avg. volume | 7,190,954 |
| Market cap | 83.659B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 14.91 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.08 (4.59%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | N/A |
- Zacks
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
- Zacks
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
© 2024 Yahoo. All rights reserved.